ZA200504657B - Drugs for chronic pain - Google Patents
Drugs for chronic pain Download PDFInfo
- Publication number
- ZA200504657B ZA200504657B ZA200504657A ZA200504657A ZA200504657B ZA 200504657 B ZA200504657 B ZA 200504657B ZA 200504657 A ZA200504657 A ZA 200504657A ZA 200504657 A ZA200504657 A ZA 200504657A ZA 200504657 B ZA200504657 B ZA 200504657B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- acid
- radical
- nitrooxymethyl
- integer
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 33
- 229940079593 drug Drugs 0.000 title claims description 33
- 239000003814 drug Substances 0.000 title claims description 33
- 208000000094 Chronic Pain Diseases 0.000 title claims description 13
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 36
- 239000002243 precursor Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229960002870 gabapentin Drugs 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- -1 dihydroxy-substituted benzyl Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229940035676 analgesics Drugs 0.000 claims description 8
- 239000000730 antalgic agent Substances 0.000 claims description 8
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 4
- DZAUWHJDUNRCTF-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 claims description 4
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 4
- 235000001785 ferulic acid Nutrition 0.000 claims description 4
- 229940114124 ferulic acid Drugs 0.000 claims description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005318 vigabatrin Drugs 0.000 claims description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- JAKXMCMUIGKSSY-ZDUSSCGKSA-N (3s)-5-methyl-3-[[[3-(nitrooxymethyl)benzoyl]amino]methyl]hexanoic acid Chemical compound CC(C)C[C@@H](CC(O)=O)CNC(=O)C1=CC=CC(CO[N+]([O-])=O)=C1 JAKXMCMUIGKSSY-ZDUSSCGKSA-N 0.000 claims description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 2
- LOQOOAHAJAAYHU-UHFFFAOYSA-N 2-[1-[(4-nitrooxybutanoylamino)methyl]cyclohexyl]acetic acid Chemical compound [O-][N+](=O)OCCCC(=O)NCC1(CC(=O)O)CCCCC1 LOQOOAHAJAAYHU-UHFFFAOYSA-N 0.000 claims description 2
- SRGKOSQAWXPLNY-UHFFFAOYSA-N 2-[1-[[[2-(nitrooxymethyl)benzoyl]oxymethoxycarbonylamino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=CC=C(CO[N+]([O-])=O)C=1C(=O)OCOC(=O)NCC1(CC(=O)O)CCCCC1 SRGKOSQAWXPLNY-UHFFFAOYSA-N 0.000 claims description 2
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 claims description 2
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 claims description 2
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
- MNNBCKASUFBXCO-YFKPBYRVSA-N N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)S MNNBCKASUFBXCO-YFKPBYRVSA-N 0.000 claims description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- 229960000959 amineptine Drugs 0.000 claims description 2
- VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229960002519 amoxapine Drugs 0.000 claims description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 235000004883 caffeic acid Nutrition 0.000 claims description 2
- 229940074360 caffeic acid Drugs 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229950010189 demexiptiline Drugs 0.000 claims description 2
- SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- 229960003472 felbamate Drugs 0.000 claims description 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 229960005219 gentisic acid Drugs 0.000 claims description 2
- BKGWACHYAMTLAF-BYPYZUCNSA-N l-thiocitrulline Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)S BKGWACHYAMTLAF-BYPYZUCNSA-N 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001158 nortriptyline Drugs 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 2
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005138 tianeptine Drugs 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 2
- LAQYHRQFABOIFD-UHFFFAOYSA-N 2-methoxyhydroquinone Chemical compound COC1=CC(O)=CC=C1O LAQYHRQFABOIFD-UHFFFAOYSA-N 0.000 claims 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 2
- GGNQRNBDZQJCCN-UHFFFAOYSA-N benzene-1,2,4-triol Chemical compound OC1=CC=C(O)C(O)=C1 GGNQRNBDZQJCCN-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- PTNLHDGQWUGONS-OWOJBTEDSA-N trans-p-coumaryl alcohol Chemical compound OC\C=C\C1=CC=C(O)C=C1 PTNLHDGQWUGONS-OWOJBTEDSA-N 0.000 claims 2
- ZJUSTWHFOVVRHU-UHFFFAOYSA-N 2-[1-[[[3-(nitrooxymethyl)phenoxy]carbonylamino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=CC(CO[N+]([O-])=O)=CC=1OC(=O)NCC1(CC(=O)O)CCCCC1 ZJUSTWHFOVVRHU-UHFFFAOYSA-N 0.000 claims 1
- IPPVWWBDLWDMEK-UHFFFAOYSA-N 2-[1-[[[4-(nitrooxymethyl)benzoyl]amino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=C(CO[N+]([O-])=O)C=CC=1C(=O)NCC1(CC(=O)O)CCCCC1 IPPVWWBDLWDMEK-UHFFFAOYSA-N 0.000 claims 1
- FBHLNVZIWOYHIZ-UHFFFAOYSA-N 4-ethoxycyclohexa-1,5-diene-1,4-diol Chemical compound CCOC1(O)CC=C(O)C=C1 FBHLNVZIWOYHIZ-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108010087806 Carnosine Proteins 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KQKWDSQFLTZOAU-ZDUSSCGKSA-N (3s)-5-methyl-3-[[[4-(nitrooxymethyl)benzoyl]amino]methyl]hexanoic acid Chemical compound CC(C)C[C@@H](CC(O)=O)CNC(=O)C1=CC=C(CO[N+]([O-])=O)C=C1 KQKWDSQFLTZOAU-ZDUSSCGKSA-N 0.000 description 1
- JXRXRJKCCGJFAH-UHFFFAOYSA-N 2-[1-[(nitrooxymethoxycarbonylamino)methyl]cyclohexyl]acetic acid Chemical compound [O-][N+](=O)OCOC(=O)NCC1(CC(=O)O)CCCCC1 JXRXRJKCCGJFAH-UHFFFAOYSA-N 0.000 description 1
- IXYATAIRCNANOQ-UHFFFAOYSA-N 2-[1-[[[3-(nitrooxymethyl)benzoyl]amino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=CC(CO[N+]([O-])=O)=CC=1C(=O)NCC1(CC(=O)O)CCCCC1 IXYATAIRCNANOQ-UHFFFAOYSA-N 0.000 description 1
- VSLHGEOOPHNXAB-UHFFFAOYSA-N 2-[1-[[[3-(nitrooxymethyl)benzoyl]oxymethoxycarbonylamino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=CC(CO[N+]([O-])=O)=CC=1C(=O)OCOC(=O)NCC1(CC(=O)O)CCCCC1 VSLHGEOOPHNXAB-UHFFFAOYSA-N 0.000 description 1
- NJVFMHPYLHQRRE-UHFFFAOYSA-N 2-[1-[[[4-(nitrooxymethyl)benzoyl]oxymethoxycarbonylamino]methyl]cyclohexyl]acetic acid Chemical compound C=1C=C(CO[N+]([O-])=O)C=CC=1C(=O)OCOC(=O)NCC1(CC(=O)O)CCCCC1 NJVFMHPYLHQRRE-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- MHPUGCYGQWGLJL-UHFFFAOYSA-N dimethyl pentanoic acid Natural products CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid group Chemical group C(\C=C/C(=O)O)(=O)O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000016254 weariness Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002658A ITMI20022658A1 (it) | 2002-12-17 | 2002-12-17 | Farmaci per il dolore cronico. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504657B true ZA200504657B (en) | 2006-03-29 |
Family
ID=32587866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504657A ZA200504657B (en) | 2002-12-17 | 2006-01-16 | Drugs for chronic pain |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7642289B2 (es) |
| EP (1) | EP1572627A1 (es) |
| JP (1) | JP4570463B2 (es) |
| KR (1) | KR20050084070A (es) |
| CN (2) | CN1729160B (es) |
| AU (1) | AU2003300252B2 (es) |
| CA (1) | CA2510283A1 (es) |
| IT (1) | ITMI20022658A1 (es) |
| MX (1) | MXPA05006730A (es) |
| NO (1) | NO20053464L (es) |
| NZ (1) | NZ540345A (es) |
| PL (1) | PL207703B1 (es) |
| RU (1) | RU2340598C2 (es) |
| WO (1) | WO2004054965A1 (es) |
| ZA (1) | ZA200504657B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| BRPI0919811B1 (pt) * | 2008-10-08 | 2022-04-19 | Xgene Pharmaceutical Inc | Conjugados de gaba e métodos de uso dos mesmos |
| US8198268B2 (en) * | 2008-10-31 | 2012-06-12 | Janssen Biotech, Inc. | Tianeptine sulfate salt forms and methods of making and using the same |
| US8062653B2 (en) * | 2009-02-18 | 2011-11-22 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
| WO2011101245A1 (en) | 2010-02-18 | 2011-08-25 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neuropathic pain |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR20180060702A (ko) * | 2016-11-29 | 2018-06-07 | 주식회사 엔씨엘바이오 | 신규 미백용 물질, 그 물질을 포함하는 조성물 및 그 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700947A (en) | 1993-10-06 | 1997-12-23 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
| KR100387359B1 (ko) | 1994-05-10 | 2003-08-27 | 니콕스 에스. 에이. | 항-염증성,비알러지성및항-혈전성을가지는니트로화합물들과그들의조성물들 |
| IT1276071B1 (it) * | 1995-10-31 | 1997-10-24 | Nicox Ltd | Compositi ad attivita' anti-infiammatoria |
| EP1031350A1 (en) * | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| SK287247B6 (sk) | 1999-06-10 | 2010-04-07 | Warner-Lambert Company Llc | Kyselina (3S,5R)-3-aminometyl-5-metyloktánová, jej použitie na výrobu liečiva a farmaceutický prostriedok s jej obsahom |
| GB2352558B (en) | 1999-06-23 | 2001-11-07 | Bookham Technology Ltd | Optical transmitter with back facet monitor |
| IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| IT1318674B1 (it) * | 2000-08-08 | 2003-08-27 | Nicox Sa | Faramaci per l'incontinenza. |
| ITMI20011308A1 (it) * | 2001-06-21 | 2002-12-21 | Nicox Sa | Farmaci per il dolore cronico |
-
2002
- 2002-12-17 IT IT002658A patent/ITMI20022658A1/it unknown
-
2003
- 2003-12-03 KR KR1020057009841A patent/KR20050084070A/ko not_active Application Discontinuation
- 2003-12-03 CN CN2003801066684A patent/CN1729160B/zh not_active Expired - Fee Related
- 2003-12-03 US US10/537,439 patent/US7642289B2/en not_active Expired - Fee Related
- 2003-12-03 WO PCT/EP2003/050932 patent/WO2004054965A1/en active Application Filing
- 2003-12-03 MX MXPA05006730A patent/MXPA05006730A/es unknown
- 2003-12-03 NZ NZ540345A patent/NZ540345A/en not_active IP Right Cessation
- 2003-12-03 PL PL377410A patent/PL207703B1/pl unknown
- 2003-12-03 CN CN201010173905A patent/CN101830824A/zh active Pending
- 2003-12-03 AU AU2003300252A patent/AU2003300252B2/en not_active Ceased
- 2003-12-03 CA CA002510283A patent/CA2510283A1/en not_active Abandoned
- 2003-12-03 JP JP2004560497A patent/JP4570463B2/ja not_active Expired - Fee Related
- 2003-12-03 RU RU2005122000/04A patent/RU2340598C2/ru not_active IP Right Cessation
- 2003-12-03 EP EP03799531A patent/EP1572627A1/en not_active Withdrawn
-
2005
- 2005-07-15 NO NO20053464A patent/NO20053464L/no not_active Application Discontinuation
-
2006
- 2006-01-16 ZA ZA200504657A patent/ZA200504657B/en unknown
-
2009
- 2009-06-02 US US12/476,717 patent/US7858665B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003300252A1 (en) | 2004-07-09 |
| CN101830824A (zh) | 2010-09-15 |
| CA2510283A1 (en) | 2004-07-01 |
| RU2340598C2 (ru) | 2008-12-10 |
| MXPA05006730A (es) | 2005-09-08 |
| ITMI20022658A1 (it) | 2004-06-18 |
| NO20053464L (no) | 2005-08-26 |
| CN1729160A (zh) | 2006-02-01 |
| EP1572627A1 (en) | 2005-09-14 |
| PL207703B1 (pl) | 2011-01-31 |
| JP4570463B2 (ja) | 2010-10-27 |
| JP2006509822A (ja) | 2006-03-23 |
| US20060270608A1 (en) | 2006-11-30 |
| PL377410A1 (pl) | 2006-02-06 |
| KR20050084070A (ko) | 2005-08-26 |
| US20090239832A1 (en) | 2009-09-24 |
| RU2005122000A (ru) | 2006-02-27 |
| CN1729160B (zh) | 2011-08-03 |
| WO2004054965A1 (en) | 2004-07-01 |
| US7858665B2 (en) | 2010-12-28 |
| US7642289B2 (en) | 2010-01-05 |
| NZ540345A (en) | 2008-05-30 |
| AU2003300252B2 (en) | 2010-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200504657B (en) | Drugs for chronic pain | |
| AU2019420189B2 (en) | Ketamine derivatives and compositions thereof | |
| EP3129023B1 (en) | Potent soluble epoxide hydrolase inhibitors | |
| US6703522B2 (en) | Alkyl amino acid derivatives useful as pharmaceutical agents | |
| US20030216469A1 (en) | Cyclic amino acid derivatives useful as pharmaceutical agents | |
| ITMI20011308A1 (it) | Farmaci per il dolore cronico | |
| SK287539B6 (sk) | Použitie peptidovej zlúčeniny na prípravu farmaceutického prostriedku na liečenie bolesti | |
| WO2014138437A1 (en) | Steroid conjugates | |
| ES2928739T3 (es) | Inhibidores de enzimas peptidil arginina desiminasa (PAD) y usos de los mismos | |
| RU2283106C2 (ru) | Производные карбаматов для использования для лечения боли | |
| US20020077342A1 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| US20130046012A1 (en) | New compounds, synthesis and use thereof in the treatment of pain | |
| JP2006509822A5 (es) | ||
| SK94796A3 (en) | Acceptability improving method of pharmaceutically effective beta-amino acids | |
| JP2009533428A (ja) | 筋肉内抗ウイルス処置 | |
| EP1321139B1 (en) | 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain | |
| EP2530072A1 (en) | New compounds, synthesis and use thereof in the treatment of pain | |
| CN117362200B (zh) | 苯甲胺类化合物及其合成方法与应用 | |
| US8343971B2 (en) | Pharmacologically-active vanilloid carbamates | |
| ES2323981T3 (es) | Tiazolopirimidinas para uso en terapia. | |
| WO2004101494B1 (es) | Inhibidores de calpaina | |
| EP4366716A1 (en) | Novel combinatorial antitumor treatment methods and related compositions, kits, and systems | |
| JP2023518205A (ja) | 酸化ストレスと関連した障害の処置およびこの処置のための化合物 | |
| DE19806713A1 (de) | Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |